References
- 1.
EUR-Lex. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions - Towards a comprehensive European international investment policy /* COM/2010/0343 final */[displayed 5 March 2024]. Available at
https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A52010DC0343 EUR-Lex Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions - Towards a comprehensive European international investment policy /* COM/2010/0343 final */[displayed 5 March 2024] Available athttps://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A52010DC0343 - Cho YJ, Yun JH, Kim SJ, Kwon HY. Nonpersistent endocrine disrupting chemicals and reproductive health of women. Obstet Gynecol Sci 2020;63:1–12. doi: 10.5468/ogs.2020.63.1.1
- 3.
United Nations Environment Programme (UNEP), World Health Organization (WHO). State of the science of endocrine disrupting chemicals – 2012. Geneva: UNEP/WHO, 2012 [displayed 6 March 2024]. Available at:
https://iris.who.int/bitstream/handle/10665/78101/9789241505031_eng.pdf?sequence=1 United Nations Environment Programme (UNEP), World Health Organization (WHO) State of the science of endocrine disrupting chemicals – 2012 Geneva UNEP/WHO 2012 [displayed 6 March 2024]. Available at:https://iris.who.int/bitstream/handle/10665/78101/9789241505031_eng.pdf?sequence=1 - Rutkowska AZ, Diamanti-Kandarakis E. Polycystic ovary syndrome and environmental toxins. Fertil Steril 2016;106:948–58. doi: 10.1016/j.fertnstert.2016.08.031
- 5.
OECD Guidelines for the Testing of Chemicals, Section 4. Test No. 455: Performance-Based Test Guideline for Stably Transfected Transactivation In Vitro Assays to Detect Estrogen Receptor Agonists and Antagonists, 2021 [displayed 5 March 2024]. Available at
https://doi.org/10.1787/9789264265295-en OECD Guidelines for the Testing of Chemicals, Section 4 Test No. 455: Performance-Based Test Guideline for Stably Transfected Transactivation In Vitro Assays to Detect Estrogen Receptor Agonists and Antagonists 2021 [displayed 5 March 2024]. Available athttps://doi.org/10.1787/9789264265295-en - Sabir S, Akhtar MF, Saleem A. Endocrine disruption as an adverse effect of non-endocrine targeting pharmaceuticals. Environ Sci Pollut Res Int 2019;26:1277–86. doi: 10.1007/s11356-018-3774-4
- Batucan NSP, Tremblay LA, Northcott GL, Matthaei CD. Medicating the environment? A critical review on the risks of carbamazepine, diclofenac and ibuprofen to aquatic organisms. Environ Adv 2022;7:100164–78. doi: 10.1016/j.envadv.2021.100164
- Küster A, Adler N. Pharmaceuticals in the environment: scientific evidence of risks and its regulation. Philos Trans R Soc Lond B Bio Sci 2014;369(1656):20130587–95. doi: 10.1098/rstb.2013.0587
- Batke M, Damm G, Foth H, Freyberger A, Gebel T, Gundert-Remy U, Hengstler J, Mangerich A, Partosch F, Röhl C, Schupp T, Wollin KM. The EU chemicals strategy for sustainability: critical reflections on proposed regulatory changes for endocrine disruptors and mixture toxicity. Arch Toxicol 2022;96:1133–5. doi: 10.1007/s00204-022-03227-z
- McEntaggart K, Chirico S, Etienne J, Rigoni M, Papoutsis S, Leather J. EFSA EU Insights Chemical mixtures awareness, understanding and risk perceptions. EFSA Support Publ 2019;EN-1602. doi: 10.2903/sp.efsa.2019.EN-1602
- OECD. Considerations for Assessment of Risk from the Combined Exposure to Multiple Chemicals. Series on Testing and Assessment No. 296, 2018 [displayed 5 March 2024]. Availble at chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/
https://www.oecd.org/chemicalsafety/risk-assessment/considerations-for-assessing-the-risks-of-combined-exposure-to-multiple-chemicals.pdf - Sharma S, Chatterjee S. Microplastic pollution, a threat to marine ecosystem and human health: a short review. Environ Sci Pollut Res Int 2017;24:21530–47. doi: 10.1007/s11356-017-9910-8
- Lehner R, Weder C, Petri-Fink A, Rothen-Rutishauser B. Emergence of nanoplastic in the environment and possible impact on human health. Environ Sci Technol 2019;53:1748–65. doi: 10.1021/acs.est.8b05512
- Katsumiti A, Losada-Carrillo MP, Barros M, Cajaraville MP. Polystyrene nanoplastics and microplastics can act as Trojan horse carriers of benzo(a)pyrene to mussel hemocytes in vitro. Sci Rep 2021;11(1):22396. doi: 10.1038/s41598-021-01938-4
- Mezzelani M, Peruzza L, D’Errico G, Milan M, Gorbi S, Regoli F. Mixtures of environmental pharmaceuticals in marine organisms: Mechanistic evidence of carbamazepine and valsartan effects on Mytilus galloprovincialis. Sci Total Environ 2023;860:160465. doi: 10.1016/j.scitotenv.2022.160465
- Batucan NSP, Tremblay LA, Northcott GL, Matthaei CD. Medicating the environment? A critical review on the risks of carbamazepine, diclofenac and ibuprofen to aquatic organisms. Environ Adv 2022;7:100164. doi: 10.1016/j.envadv.2021.100164
- Ács A, Liang X, Bock I, Griffitts J, Ivánovics B, Vásárhelyi E, Ferincz Á, Pirger Z, Urbányi B, Csenki Z. Chronic effects of carbamazepine, progesterone and their mixtures at environmentally relevant concentrations on biochemical markers of zebrafish (Danio rerio). Antioxidants 2022;11(9):1776. doi: 10.3390/antiox11091776
- Almeida Â, Soares AMVM, Esteves VI, Freitas R. Occurrence of the antiepileptic carbamazepine in water and bivalves from marine environments: A review. Environ Toxicol Pharmacol 2021;86:103661. doi: 10.1016/j.etap.2021.103661
- Mezzelani M, Nardi A, Bernardini I, Milan M, Peruzza L, d’Errico G, Fattorini D, Gorbi S, Patarnello T, Regoli F. Environmental pharmaceuticals and climate change: The case study of carbamazepine in M. galloprovincialis under ocean acidification scenario. Environ Int 2021;146:106269. doi: 10.1016/j.envint.2020.106269
- Correia D, Domingues I, Faria M, Oliveira M. Effects of fluoxetine on fish: What do we know and where should we focus our efforts in the future? Sci Total Environ 2023;857:159486. doi: 10.1016/j.scitotenv.2022.159486
- Nentwig G. Effects of pharmaceuticals on aquatic invertebrates. Part II: the antidepressant drug fluoxetine. Arch Environ Contam Toxicol 2007;52:163–70. doi: 10.1007/s00244-005-7190-7
- Oakes KD, Coors A, Escher BI, Fenner K, Garric J, Gust M, Knacker T, Küster A, Kussatz C, Metcalfe CD, Monteiro S, Moon TW, Mennigen JA, Parrott J, Péry AR, Ramil M, Roennefahrt I, Tarazona JV, Sánchez-Argüello P, Ternes TA, Trudeau VL, Boucard T, Van Der Kraak GJ, Servos MR. Environmental risk assessment for the serotonin re-uptake inhibitor fluoxetine: Case study using the European risk assessment framework. Integr Environ Assess Manag 2010;6(Suppl):524–39. doi: 10.1002/ieam.77
- Yamindago A, Lee N, Lee N, Jo Y, Woo S, Yum S. Fluoxetine in the environment may interfere with the neurotransmission or endocrine systems of aquatic animals. Ecotoxicol Environ Saf 2021;227:112931. doi: 10.1016/j.ecoenv.2021.112931
- Correia D, Bellot M, Prats E, Gómez-Canela C, Moro H, Raldúa D, Domingues I, Oliveira M, Faria M. Impact of environmentally relevant concentrations of fluoxetine on zebrafish larvae: from gene to behavior. Chemosphere 2023;345:140468. doi: 10.1016/j.chemosphere.2023.140468
- Lupu D, Sjödin MOD, Varshney M, Lindberg J, Loghin F, Rüegg J. Fluoxetine modulates sex steroid levels in vitro. Clujul Med 2017;90:420–4. doi: 10.15386/cjmed-868
- Jacobsen NW, Hansen CH, Nellemann C, Styrishave B, Halling-Sørensen B. Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol in Vitro 2015;29:1729–35. doi: 10.1016/j.tiv.2015.07.005
- Pop A, Lupu DI, Cherfan J, Kiss B, Loghin F. Estrogenic/antiestrogenic activity of selected selective serotonin reuptake inhibitors. Clujul Med 2015;88:381–5. doi: 10.15386/cjmed-474
- Müller JC, Imazaki PH, Boareto AC, Lourenço EL, Golin M, Vechi MF, Lombardi NF, Minatovicz BC, Scippo ML, Martino-Andrade AJ, Dalsenter PR. In vivo and in vitro estrogenic activity of the antidepressant fluoxetine. Reprod Toxicol 2012;34:80–5. doi: 10.1016/j.reprotox.2012.04.001
- 29.
USEPA. Endocrine Disruptor Screening Program Test Guidelines - OPPTS 890.1300: Estrogen Receptor Transcriptional Activation (Human Cell Line (HeLa-9903)) [EPA 740-C-09-006] [displayed 5 March 2024]. Available at
https://www.regulations.gov/document/EPA-HQ-OPPT-2009-0576-0006 USEPA Endocrine Disruptor Screening Program Test Guidelines - OPPTS 890.1300: Estrogen Receptor Transcriptional Activation (Human Cell Line (HeLa-9903)) [EPA 740-C-09-006] [displayed 5 March 2024]. Available athttps://www.regulations.gov/document/EPA-HQ-OPPT-2009-0576-0006 - Wilson VS, Bobseine K, Gray LE Jr. Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists. Toxicol Sci 2004;81:69–77. doi: 10.1093/toxsci/kfh180
- Shen M, Zhang Y, Zhu Y, Song B, Zeng G, Hu D, Wen X, Ren X. Recent advances in toxicological research of nanoplastics in the environment: A review. Environ Pollut 2019;252:511–21. doi: 10.1016/j.envpol.2019.05.102
- Ali I, Cheng Q, Ding T, Yiguang Q, Yuechao Z, Sun H, Peng C, Naz I, Li J, Liu J. Micro- and nanoplastics in the environment: Occurrence, detection, characterization and toxicity – A critical review. J Clean Prod 2021;313:127863. doi: 10.1016/j.jclepro.2021.127863
- Xu JL, Lin X, Wang JJ, Gowen AA. A review of potential human health impacts of micro- and nanoplastics exposure. Sci Total Environ 2022;851:158111. doi: 10.1016/j.scitotenv.2022.158111
- Malich G, Markovic B, Winder C. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 1997;124(3):179–92. doi: 10.1016/S0300-483X(97)00151-0
- Sakuratani Y, Horie M, Leinala E. Integrated approaches to testing and assessment: OECD activities on the development and use of adverse outcome pathways and case studies. Basic Clin Pharmacol Toxicol 2018;123(Suppl 5):20–8. doi: 10.1111/bcpt.12955
- Delrue N, Sachana M, Sakuratani Y, Gourmelon A, Leinala E, Diderich R. The adverse outcome pathway concept: A basis for developing regulatory decision-making dools. Altern Lab Anim 2016;44:417–29. doi: 10.1177/026119291604400504
- Vinken M. The adverse outcome pathway concept: A pragmatic tool in toxicology. Toxicology 2013;312:158–65. doi: 10.1016/j.tox.2013.08.011